Tolerability of Enecadin (INN) in Acute Ischemic Stroke Trial - TEST


Phase 2 Results N/A

Summary of Purpose

The main objective of this study is to investigate the tolerability of enecadin in patients with acute ischemic stroke. Furthermore, the pharmacokinetics of enecadin in both male and female patients with acute ischemic stroke will be assessed. Efficacy trends will be evaluated up to day 30 post stroke. Trial Stopped: Scientific data called into question the viability of the substance class

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 21 May 2008.

1 May 2006 30 May 2006 1 May 2009 1 May 2009 1 May 2008 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics




Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator)
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Parallel Assignment


  • Amgad Shebl Clinical Development PAION Deutschland GmbH Martinstrasse 10-12 52062 Aachen . Germany Phone: +49-241-4453-235 Fax: +49-241-4453-233